Table 1 Enrichment analysis of genes under positive selection in humans
Term | Input (Background) | Corrected p value |
|---|---|---|
Pathway (top 15 terms) | ||
 Gene expression (transcription) | 84 (1448) | 2.74E − 07 |
 Immune system | 109 (2096) | 2.74E − 07 |
 Generic transcription pathway | 73 (1193) | 4.28E − 07 |
 RNA polymerase II transcription | 76 (1316) | 1.93E − 06 |
 Metabolism | 103 (2075) | 6.27E − 06 |
 Adaptive immune system | 48 (748) | 5.72E − 05 |
 Metabolic pathways | 74 (1433) | 1.25E − 04 |
 Chemical carcinogenesis | 13 (82) | 3.28E − 04 |
 Metabolism of xenobiotics by cytochrome P450 | 12 (76) | 7.49E − 04 |
 Metabolism of proteins | 91 (2012) | 9.01E − 04 |
 Post-translational protein modification | 69 (1412) | 1.13E − 03 |
 Innate immune system | 55 (1043) | 1.28E − 03 |
 Drug metabolism—cytochrome P450 | 11 (72) | 1.89E − 03 |
 Cell cycle | 38 (629) | 1.89E − 03 |
 Transcriptional regulation by TP53 | 26 (359) | 2.34E − 03 |
Disease (top 15 terms) | ||
 Schizophrenia | 20 (181) | 1.37E − 04 |
 Obesity-related traits | 44 (691) | 1.87E − 04 |
 Longevity | 9 (32) | 2.44E − 04 |
 Platelet counts | 11 (77) | 2.91E − 03 |
 Age-related macular degeneration | 10 (64) | 3.29E − 03 |
 Alzheimer’s disease | 8 (47) | 8.16E − 03 |
 Other diseases | 17 (204) | 8.33E − 03 |
 Mental and behavioral disorders | 16 (189) | 9.83E − 03 |
 Alzheimer’s disease (late onset) | 8 (50) | 1.00E − 02 |
 Autism | 5 (15) | 1.00E − 02 |
 Metabolite levels (HVA/MHPG ratio) | 5 (17) | 1.45E − 02 |
 Congenital disorders of metabolism | 36 (695) | 2.06E − 02 |
 Gambling | 4 (10) | 2.10E − 02 |
 Nervous system diseases | 42 (859) | 2.11E − 02 |
 Bipolar disorder | 12 (131) | 2.39E − 02 |
GO (top 15 terms with < 500 background genes) | ||
 Glutamatergic synapse | 27 (354) | 9.44E − 04 |
 Signaling receptor activity | 20 (214) | 9.90E − 04 |
 Neuron projection | 26 (336) | 1.04E − 03 |
 Transcription factor binding | 25 (325) | 1.58E − 03 |
 Glucuronosyltransferase activity | 7 (23) | 1.71E − 03 |
 Brain development | 20 (231) | 2.24E − 03 |
 Ubiquitin protein ligase binding | 23 (294) | 2.34E − 03 |
 Protein kinase binding | 30 (461) | 3.39E − 03 |
 Amyloid-beta binding | 11 (80) | 3.55E − 03 |
 Neuronal cell body | 26 (376) | 4.17E − 03 |
 Neuron projection development | 13 (116) | 4.72E − 03 |
 Postsynaptic density | 20 (251) | 5.02E − 03 |
 Flavone metabolic process | 4 (5) | 5.45E − 03 |
 Chaperone cofactor-dependent protein refolding | 7 (32) | 6.36E − 03 |
 mRNA 3'-UTR binding | 10 (73) | 6.69E − 03 |